Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
OBJECTIVE
Androgen-deprivation therapy for prostate cancer decreases bone mineral density and increases the risk of fracture. The effect of risedronate, a potent third-generation oral bisphosphonate, on bone loss during androgen deprivation therapy was investigated.


METHODS
Sixty-one prostate cancer patients with a mean age (+/- SD) of 79 +/- 6 years who had received androgen deprivation therapy for 42 +/- 29 months were enrolled, and were treated with 2.5 mg of risedronate daily for six months. Bone mineral density was measured at the femoral neck, lumbar spine, and ultradistal radius by dual energy X-ray absorptiometry. The percent change of bone mineral density after treatment with risedronate was calculated as the primary efficacy variable. Urinary N-telopeptide of type I collagen was measured as a bone resorption marker.


RESULTS
Bone mineral density remained stable in the femoral neck and radius during risedronate therapy. In contrast, the bone mineral density of the lumbar spine showed a significant increase from 1069 +/- 488 mg/cm(2)-1112 +/- 497 mg/cm(2) (P < 0.001), representing a gain of 4.9 +/- 8.9%. Urinary N-telopeptide of type I collagen decreased significantly (P < 0.001) after three months of risedronate treatment.


CONCLUSIONS
Risedronate could prevent and reverse bone loss in men receiving androgen deprivation therapy for prostate cancer by inhibiting bone resorption.
Ishizaka
Kazuhiro
K
Department of Urology, Kanto Central Hospital, Tokyo, Japan. ishizaka@kanto-ctr-hsp.com
Machida
Tatsuya
T
Kobayashi
Shuichiro
S
Kanbe
Naoko
N
Kitahara
Satoshi
S
Yoshida
Ken-Ichiro
K
D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use*; D000728:Androgens / Q000172:deficiency*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced* / Q000378:metabolism / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D000068296:Risedronic Acid
D000726:Androgen Antagonists; D000728:Androgens; D050071:Bone Density Conservation Agents; D007987:Gonadotropin-Releasing Hormone; D000068296:Risedronic Acid; D012968:Etidronic Acid